SHINE acquires North Billerica manufacturing facility and established SPECT product portfolio, expanding leadership in nuclear medicine.
Read the press release here.
SHINE has completed its acquisition of Lantheus' SPECT business, including the North Billerica, Massachusetts manufacturing facility and its portfolio of diagnostic radiopharmaceuticals.
The portfolio includes TechneLite® (Technetium Tc 99m Generator), Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), NEUROLITE® (Kit for the Preparation of Technetium Tc99m Bicisate for Injection), and Xenon Xe-133 Gas for pulmonary imaging — products serving hospitals and imaging centers across North America in millions of procedures annually.
The acquisition integrates manufacturing expertise, customer relationships, and established market position into SHINE's nuclear medicine business. The North Billerica SPECT facility will operate under SHINE SPECT USA, LLC, adding proven production capabilities to SHINE's platform.
“The nuclear medicine supply chain needs to be modernized to keep up with patient needs,” says Greg Piefer, founder and CEO SHINE Technologies.
“We're building that now, bringing new technology to bear across both diagnostic and therapeutic markets. This strengthens the entire isotope supply ecosystem and positions SHINE to deliver the reliability healthcare depends on."
%20(5).jpg)
EXECUTIVE APPOINTMENT
To lead the integration and growth of the SPECT business, SHINE has named Michael Rossi as CEO of SHINE SPECT USA, LLC.
"Mike's thirty years of experience in radiopharmaceuticals makes him the right leader to integrate and grow our SPECT operations," said Piefer.
“I'm excited to join SHINE at this pivotal moment. The SPECT team has built strong customer relationships and operational excellence over decades. Combining that foundation with SHINE's expanding production capabilities creates the integrated platform the nuclear medicine market needs. I'm looking forward to working with this team to strengthen supply chain security for our customers and patients,” said Michael Rossi.
Chrysalis, currently under development in Janesville, Wisconsin, is designed to become the largest isotope production facility in the world. Using fusion-based technology, Chrysalis will produce Mo-99, Xe-133, and other isotopes that will supply the SPECT business—creating an integrated supply chain from production through distribution to patients.
With this acquisition, SHINE's nuclear medicine platform now spans both diagnostic and therapeutic applications.
